India, Sept. 3 -- Valneva SE(VALN,VLA.PA) announced positive immunogenicity and safety results from its ongoing Phase 2 clinical trial of the Lyme disease vaccine candidate, VLA15. The data show a strong anamnestic immune response and a favorable safety profile following administration of a third booster dose. The findings align with previous results from earlier annual boosters, reinforcing the vaccine's potential for seasonal, yearly use ahead of Lyme disease exposure periods.
There are currently no approved human vaccines for Lyme disease, and VLA15 has advanced the furthest in clinical development, with two Phase 3 trials nearing completion.
The company noted that the safety and tolerability profile of VLA15 after the third booster do...